接受索拉非尼治疗的肝细胞癌患者循环内皮细胞与疾病进展风险
Circulating endothelial cells and risk of progression in patients with hepatocellular cancer receiving sorafenib.
作者信息
Giovanis Petros, Pianezze Graziano, Vincenzi Valter, Manuppelli Carla, Boaretto Massimo, Pastorelli Davide
机构信息
Medical Oncology Unit, City Hospital of Feltre, Via Bagnols Sul Ceze 3, 32032, Ulss 1 Dolomiti, Feltre, Italy.
Research Lab, City Hospital of Belluno, Belluno, Ulss 1 Dolomiti, Italy.
出版信息
Hepat Oncol. 2017 Apr;4(2):39-43. doi: 10.2217/hep-2016-0011. Epub 2017 Sep 8.
AIM
We investigated the behavior of circulating endothelial cells (CEC) in patients with hepatocellular carcinoma (HCC) receiving sorafenib, and whether CEC levels were associated with time to progression (TTP).
MATERIALS & METHODS: CECs in advanced HCC patients receiving sorafenib were counted at baseline and every 4 weeks.
RESULTS
Twenty four HCC patients were enrolled in the study. Median TTP was 3.2 months (1-6). Median baseline CEC levels were 67 cells/ml, with an increase of 169.8% after 4 weeks of treatment. Any time CEC levels in patients with a TTP lower than 4 months were higher, but not statistically significant, compared with those in patients with TTP more than 4 months.
CONCLUSION
Treatment with sorafenib changed CEC levels in HCC patients.
目的
我们研究了接受索拉非尼治疗的肝细胞癌（HCC）患者循环内皮细胞（CEC）的行为，以及CEC水平是否与疾病进展时间（TTP）相关。
材料与方法
对接受索拉非尼治疗的晚期HCC患者在基线时及每4周计数一次CEC。
结果
24例HCC患者纳入本研究。TTP的中位数为3.2个月（1 - 6个月）。基线时CEC水平的中位数为67个细胞/毫升，治疗4周后增加了169.8%。TTP低于4个月的患者在任何时间的CEC水平均高于TTP超过4个月的患者，但差异无统计学意义。
结论
索拉非尼治疗改变了HCC患者的CEC水平。
Zotero 插件